	US 7,541,339 B2
	Par-2-activating peptide derivative and pharmaceutical composition using the same
Robert Ramage, Lothian (United Kingdom); Robin Plevin, Strathclyde (United Kingdom); Kevin Thomas Shaw, Lothian (United Kingdom); Lu Jiang, Dallan (China); Louise Claire Young, Strathclyde (United Kingdom); Alan Lang Harvey, Strathclyde (United Kingdom); Pu Wang, Edinburgh (United Kingdom); Toru Kanke, Musashino (Japan); Junichi Kawagoe, Kawagoe (Japan); and Mototsugu Kabeya, Higashimurayama (Japan)
Assigned to The University of Edinburgh, Lothian (United Kingdom); The University of Strathclyde, Strathclyde (United Kingdom); and Kowa Company, Ltd., Aichi (Japan)
Appl. No. 10/517,803 PCT Filed Jun. 10, 2003, PCT No. PCT/JP03/07333 § 371(c)(1), (2), (4) Date Dec. 10, 2004, PCT Pub. No. WO03/104268, PCT Pub. Date Dec. 18, 2003.
Claims priority of application No. 0213286.8 (GB), filed on Jun. 10, 2002.
Prior Publication US 2005/0222384 A1, Oct. 06, 2005
Int. Cl. A61K 38/08 (2006.01); C07K 7/06 (2006.01)

U.S. Cl. 514—17 [530/330]

7 Claims

1. A peptide derivative represented by the general formula (I) or a salt thereof:

Z-CO—NH-Leu-Ile-Gly-AA₁-AA₂-CO—R (I)

wherein Z represents a furyl group; AA₁-AA₂represents Lys-Val or Arg-Leu; and R represents —OH or —NH₂.